Clinuvel Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Clinuvel Pharmaceuticals Il CEO è Philippe Wolgen, nominato in Nov2005, e ha un mandato di 19.08 anni. la retribuzione annua totale è A$ 3.74M, composta da 47.2% di stipendio e 52.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 6.86% delle azioni della società, per un valore di A$ 46.65M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.9 anni e 5 anni.

Informazioni chiave

Philippe Wolgen

Amministratore delegato

AU$3.7m

Compenso totale

Percentuale dello stipendio del CEO	47.2%
Mandato del CEO	19yrs
Proprietà del CEO	6.9%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Philippe Wolgen rispetto agli utili di Clinuvel Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	AU$4m	AU$2m	AU$36m
Mar 31 2024	n/a	n/a	AU$33m
Dec 31 2023	n/a	n/a	AU$30m
Sep 30 2023	n/a	n/a	AU$30m
Jun 30 2023	AU$6m	AU$2m	AU$31m
Mar 31 2023	n/a	n/a	AU$29m
Dec 31 2022	n/a	n/a	AU$26m
Sep 30 2022	n/a	n/a	AU$24m
Jun 30 2022	AU$7m	AU$1m	AU$21m
Mar 31 2022	n/a	n/a	AU$22m
Dec 31 2021	n/a	n/a	AU$24m
Sep 30 2021	n/a	n/a	AU$24m
Jun 30 2021	AU$5m	AU$2m	AU$25m
Mar 31 2021	n/a	n/a	AU$23m
Dec 31 2020	n/a	n/a	AU$21m
Sep 30 2020	n/a	n/a	AU$18m
Jun 30 2020	AU$3m	AU$2m	AU$15m
Mar 31 2020	n/a	n/a	AU$15m
Dec 31 2019	n/a	n/a	AU$15m
Sep 30 2019	n/a	n/a	AU$16m
Jun 30 2019	AU$1m	AU$894k	AU$18m
Mar 31 2019	n/a	n/a	AU$17m
Dec 31 2018	n/a	n/a	AU$16m
Sep 30 2018	n/a	n/a	AU$15m
Jun 30 2018	AU$2m	AU$818k	AU$13m

Compensazione vs Mercato: La retribuzione totale di Philippe ($USD 2.43M ) è superiore alla media delle aziende di dimensioni simili nel mercato Australian ($USD 928.86K ).

Compensazione vs guadagni: La retribuzione di Philippe è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Philippe Wolgen (61 yo)

19yrs

Mandato

AU$3,742,412

Compensazione

Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Philippe Wolgen	CEO, MD & Director	19yrs	AU$3.74m	6.86% A$ 46.7m
Dennis Wright	Chief Scientific Officer	12.2yrs	AU$782.61k	0.38% A$ 2.6m
Peter Vaughan	Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Lachlan Hay	Chief Operations Officer	no data	Nessun dato	Nessun dato
Malcolm Bull	Head of Australian Operations & Investor Relations	no data	Nessun dato	Nessun dato
Rose Quadbeck-Diel	Senior Vice President of Regulatory Affairs	less than a year	Nessun dato	Nessun dato
Azza Hamila	Head of Quality Assurance & Drug Safety	less than a year	Nessun dato	Nessun dato
Claire Newstead-Sinclair	Company Secretary	less than a year	Nessun dato	Nessun dato

0.9yrs

Durata media

Gestione esperta: Il team dirigenziale di CUV non è considerato esperto (durata media 0.9 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Philippe Wolgen	CEO, MD & Director	19.1yrs	AU$3.74m	6.86% A$ 46.7m
Pearl Grimes	Non-Executive Director	less than a year	Nessun dato	Nessun dato
Matthew Pringle	Non-Executive Director	less than a year	Nessun dato	Nessun dato
Susan Smith	Non-Executive Director	5.2yrs	AU$80.00k	0.00084% A$ 5.7k
Jeffrey Rosenfeld	Non-Executive Chairman	5yrs	AU$91.67k	0.0063% A$ 42.9k
Karen Agersborg	Non-Executive Director	6.8yrs	AU$75.00k	0.028% A$ 188.4k
Guy van Dievoet	Non-Executive Director	less than a year	Nessun dato	Nessun dato

5.0yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CUV sono considerati esperti (durata media dell'incarico 5 anni).

Clinuvel Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

No independent directors

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022

Recent updates

CLINUVEL Files Canadian New Drug Submission for SCENESSE® in EPP

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024

Dividend of AU$0.05 announced

Full year 2024 earnings released: EPS: AU$0.71 (vs AU$0.62 in FY 2023)

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

CLINUVEL Announces A Novel Clinical Program

Investor sentiment deteriorates as stock falls 17%

First half 2024 earnings released: EPS: AU$0.22 (vs AU$0.23 in 1H 2023)

Clinuvel Pharmaceuticals Limited to Report First Half, 2024 Results on Feb 22, 2024

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023

Full year 2023 earnings released: EPS: AU$0.62 (vs AU$0.42 in FY 2022)

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

Investor sentiment deteriorates as stock falls 19%

Now 22% undervalued

Clinuvel Pharmaceuticals Ltd Announces the Completion of Manufacture of the First cGMP Batch of PRÉNUMBRA® Instant

Clinuvel Pharmaceuticals Limited Announces First Positive Results from Study Evaluating the Protective Effects of Afamelanotide on Skin Exposed to Ultraviolet Radiation

Clinuvel Pharmaceuticals Limited Announces Neuracthel Manufacturing Processes Advance

Clinuvel Pharmaceuticals Limited Shares the First Results of Phase II Study Evaluating Afamelanotide in Patients with Xeroderma Pigmentosum

No independent directors

Clinuvel Pharmaceuticals Limited Announces Enrollment of First Patient in New Clinical Study CUV104

Investor sentiment improved over the past week

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022

Full year 2022 earnings released: EPS: AU$0.42 (vs AU$0.50 in FY 2021)

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2022, Payable on September 21, 2022

Investor sentiment improved over the past week

CLINUVEL PHARMACEUTICALS LIMITED Intends to Evaluate its Drug Candidate PRÉNUMBRA Instant (Afamelanotide) as A Treatment for Patients Diagnosed with Arterial Ischaemic Stroke (AIS) in its Next Clinical Trial (CUV803)

Investor sentiment improved over the past week

Non-Executive Director recently sold AU$356k worth of stock

CLINUVEL Progresses CUV104 Vitiligo Study

CLINUVEL Releases Positive Final Results of the Open Label Pilot Study (CUV801) in Arterial Ischemic Stroke

No independent directors

Clinuvel Pharmaceuticals Ltd Appoints Andrew Likierman as New Non-Executive Director

Clinuvel Pharmaceuticals Limited Announces First XP-V Patient Treated in Third CUV DNA Repair Study

CEO, MD & Director recently sold AU$1.1m worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Now 28% undervalued after recent price drop

Clinuvel Pharmaceuticals Limited Completes Enrolment in CUV801 Stroke Study

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS AU$0.50 (vs AU$0.31 in FY 2020)

CEO, MD & Director recently sold AU$3.7m worth of stock

Non-Executive Director recently sold AU$692k worth of stock

Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with Afamelanotide

CEO, MD & Director recently sold AU$3.1m worth of stock

CEO, MD & Director recently sold AU$2.6m worth of stock

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2021 Results on Aug 31, 2021

Investor sentiment improved over the past week

Revenue misses expectations

First half 2021 earnings released: EPS AU$0.13 (vs AU$0.013 in 1H 2020)

New 90-day low: AU$20.11

Clinuvel Pharmaceuticals Limited to Report First Half, 2021 Results on Feb 26, 2021

Clinuvel Pharmaceuticals Limited Announces First Patient Dosed in SCENESSE DNA Repair Program

New 90-day low - AU$21.04

Earnings released

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media